<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/229390-2-cyanopyrrolopyrimidines-and-process-for-preparing-the-same by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 10:04:46 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 229390:2-CYANOPYRROLOPYRIMIDINES AND PROCESS FOR PREPARING THE SAME</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">2-CYANOPYRROLOPYRIMIDINES AND PROCESS FOR PREPARING THE SAME</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention relates to pyrrolo pyrimidines of formula (I), wherein Y represents -(CH2)t-0- or -(CH2)r-S-, p is 1 or 2, r is 1, 2 or 3, t is 1, 2 or 3, or Y is -(CH2)j- or -CH=CH-, j is 1 or 2; p is 1 or 2, or Y is -(CH2)f-, f is 1 or 2, p is 1, and the further radicals and symbols have the meaning as defined herein; their preparation, their use as pharmaceuticals, pharmaceutical compositions containing them, the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment of neuropathic pain and to a method for the treatment of such a disease in animals, especially in humans.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>CLAIMS:<br>
1. A pyrrolo pyrimidine of formula I,<br><br>
wherein<br>
Y represents -(CH2)rO- or -(CH2)rS-,<br>
p is 1 or 2,<br>
ris 1,2 or 3,<br>
t is 1,2 or 3,<br>
R1 represents<br>
(h) phenyl which is unsubstituted or mono-, di- or trisubstituted by<br>
(a) halogen, carboxy, alkoxy, nitro, alkyl-C(0)-NH-, cyc!oalkyl-C(0)-NH-, alkyl-C(O)-N(alkyl)-, formyl, alkyl-C(O)-, alkyl-S(0)2-NH-, CF3-alkyl-S(0)2-NH-, pyrrolidinyl carbonyl, piperidinyl carbonyl, morpholinyl carbonyl, N-alkyl piperazinyl carbonyl, piperidinyl, 1-(alkyl carbonyl) piperidinyl, 1,2,3,6-tetrahydropyridyl, alkyl carbonyl 1,2,3,6-tetrahydropyridyl, piperazinyl, alkyl piperazinyl, alkyl carbonyl piperazinyl, cycloalkyl carbonyl piperazinyl, alkoxy carbonyl piperazinyl, alkyl-S02-piperazinylf diazacycloheptyl, alkyl carbonyl diazacycloheptyl, 2-oxo-1-pyrrolidinyl, 3,3-di-alkyl-2-oxo-1-pyrrolidinyl;<br>
(P) R3-alkyl, wherein R3 represents hydrogen, hydroxy, carboxy, alkyl-N(alkyl)-, all^yl-NH-, 1-pyrrolidinyl, 1-piperidyl, 4-alkyl-1-piperazinyl carbonyl, 2,4-dioxa-5,5-(di-alkyl)-oxazolidin-3-yl, R4R5N-C(0)-, wherein R4 and R5 independently of each other represent hydrogen or alkyl; or<br>
(y) RaR7N-C(0)-, wherein R6 and R7 independently of each other represent hydrogen, alkyl, cycloalkyl alkyl, CF3-alkyl or pyridyl alkyl; (i) pyridyl, which is unsubstituted or mono-, di- or trisubstituted by halogen or alkyl which<br>
is mono-, di- or trisubstituted by halogen; (j) pyrimidyl;<br><br>
(k) indoiyl, which is mono^ or disubstituted by alkyl-C(0)-NH-alkyl; (I) 2-(alkyl)-benzothiazolyl; (m)a radical of subformula la<br><br>
wherein Ra IS hydrogen, halogen or alkyl, R9 is hydrogen or alkyl, and m h 1, 2, 3 or 4; or (n) a radical of subformula lb<br><br>
wherein R10 is hydrogen, halogen or alkyl, Rn is hydrogen or alkyl, and n is 1,2, 3 or 4; R2 represents alkyl, which is unsubstituted or substituted by cycloalkyl, which is<br>
unsubstituted or mono- or disubstituted by halogen, or phenyl, which Is mono- or<br>
disubstituted by halogen; under the proviso that R2 does not represent 1,1-dimethylethyl if Y is O and R^ is selected<br>
from 3-pyridyl, 4-pyrldyl, 5-chioro-3-pyridyl, 6-chloro-3-pyridyl, 2-chloro-4-pyridyl, 2-<br>
trifluoromethyl-4-pyridyl, 2-difluoromethyl-4-pyridyl, 4-acetyl-1-piperazinyl-phenyl, 4-<br>
methyl-1-piperazinyl-methyl-phenyl,and under the proviso that R2 does not represent 1,1-dimethylethyl, if Y is S and Ri is 4-pyridyl;<br>
or<br>
Yis^CH2)ror-~CH=CH-,<br>
jis1or2;<br>
p is 1 or 2,<br><br>
Ri represents<br>
(c)	thienyl, thiazolyl, 1-piperidinyl-carbonyl, or<br>
(d)	phenyl which is unsubstituted or mono-, di- or trisubstituted by<br>
(i) alkoxy, H2N-C(0)-, 4-(alkyl carbonyl) 1-piperazinyl, 2-oxo-1-pyrrolidinyl, or<br>
halogen;<br>
(ii) Ri2-0-C(0)-t wherein Ri2is hydrogen or alkyl, or<br>
(iii) R13NH-, wherein R13 represents hydrogen or a radical R14-alkyl-Z-, wherein Z is<br>
CO, SO or S02 and R14 denotes hydrogen, trifluoromethyl or alkoxy,<br>
(iv) Ri5-alkyl, wherein R15 denotes hydrogen, hydroxy, lalkoxy, 1-pyrrolidinyl, 2-oxo-1-<br>
pyrrolidinyl, imidazolidin-2,5-dion-1-yl, 5,5-di-alkyI-oxazolidin-2,4-dion-3-yl or alkyl-<br>
M(R™)-&gt; wherein Ri6 represents hydrogen or alkyi; and<br>
•'* ■■■!i-     ..-•■■■■■■■.-■<br>
R2 represents<br>
(a)	alkyl, which is unsubstituted or substituted by alkenyl, indanyl, cycloalkyl which is unsubstituted or mono- or disubstituted by halogen or alkyl, cycloalkenyl, phenyl, which is unsubstituted or mono- or disubstituted by halogen or by alkyl;<br>
(b)	cycloalkyl; or<br>
(c)	alkylcarbonyl;<br>
under the proviso that, if Y is CH2) Ri represents 4-chlorophenyl and p is 1, R2 does not denote 1,1-dimethylethyl, 1-methylethyl, cyclopropyl, cyclohexyl, 2-methyl-propyl or 2-ethyl-propyl;<br>
under the proviso that R2 does not represent 1,1-dimethylethyl, if p is 1, Y is CH2 and R, represents thienyl, phenyl, methoxyphenyl, propoxyphenyl, 4-fluorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-butylphenyl, hydroxymethylphenyl, 4-(5,5-dimethyl-oxazolidin-2,4-dion-3-yl-methyl)-phenylf 4-(methylsulfonylamino)-phenyl,4-(n-butyl-sulfonylamino)-phenyl, 4-(ethylsulfonylamino)-phenyl, 4-(n-propyIsulfonylamino)-phenyl, 4-(iso-propylsulfonylamino)-phenyl, 4-aminophenyl, 4-(acetylamino)-phenyl, 4-(butanoylamino)-phenyl or 4-(diethylaminomethyl)-phenyl;<br>
and under the proviso that that R2 does not represent 1-methylethyl, if p is 1, Y is CH2 and Ri represents phenyl which is unsubstituted or substituted by 4-acetyl-1-piperazinyl; or<br>
Y is -<ch2></ch2>
fis1or2;<br>
pis1f<br><br>
Ri represents<br>
(a)	1,2,3,6-tetrahydropyrkM-yl, alW-1.2,3,6-tetrahydropyrid-1-ylf di-alkyl-1,2,3,6-tetrahydropyrid-1-yl, halo-1,2,3,6-tetrahydropyrid-1-yl, phenyl-1,2,3,6-tetrahydropyrid-1-yl, imidazolyl, alkyl imidazolyl, di-halo imidazolyl, imidazolidin-2,5-dion-1-yl, 5,5-dilalkyl-oxazolidin-2,4-dion-3-yl, alkyl imidazolidin-2,5-dion-1-yl, trifluoromethyl-3,4-pyrrolin-1-yl, pyrrolidinyl, alkyl 1-pyrrolidinyl, di-alkyl) pyrrolidinyl, alkoxy pyrrolidinyl, alkyl 2-oxo-1-pynrolidinyl, di-alkyl 2-oxo-1-pyrrolidinyl, halo 1-pyrrolidinyl, di-halo 1-pyrrolidinyl, di-halo 1-piperidinyl, triazolyl, nitro triazolyl, phenyl imidazolyl, tetrazolyl, benzo[b]imidazolyl, (1-(alkyl-S02)-4-piperidinyl)-2,3-dihydro-2-oxo-benzo[b]imidazolyl, 3-(alkyl carbonyl-4-piperidinyl)-2,3-dihydro-2-oxo-benzo[b]imidazolylt indolyl, halo 1-indolyl, 1,3-dihydro-2-isoinddlyl, 2,3-dihydro-1-indolyl, 2,3-dlhydro-2-oxo-benzo[b]thiazolyl, di-alkoxv 1,2,3,4-tetrahydroquinnolin, alkoxy-1,2,3,4-tetrahydroisoquinnolin;<br>
(b)	a radical of substructure Ic<br><br>
which is bound to the molecule via the nitrogen atom, wherein<br>
X is -0-, -(CH2)s-CRi7Rie- or -NR18, wherein<br>
s is 0,1 or 2, R17 and R18 are independently selected from hydrogen, halogen, hydroxy,<br>
alkyl, phenyl alkyl carbonyl, carbamoyl, N-phenyl carbamoyl, cyano, pyridyl, piperidinyl<br>
and phenyl which is unsubstituted or mono- or disubstituted by halogen or alkoxy, or, if X<br>
is CR|7R18, Ri7 and R18 and together form an oxo group or a group HO-C(0)-CH=, and<br>
R23t R24, R25 and R26 are independently selected from hydrogen and alkyl;<br>
(c)	a radical of substructure Id<br><br><br>
which is bound to the molecule via the nitrogen atom, wherein<br>
k is 0,1 or 2, A is CH2 or a bond, B is CH2 or carbonyl, D is CH2 or carbonyl, E is CH2 or<br>
NR^, G is CH2 or a bond, Q is CH2 or carbonyl, T is CH2 or NR29, R19 represents<br>
hydrogen, alkyl, phenyl alkyl, alkyl carbonyl or alkyl-S02-f R^ is hydrogen or alkyl and R29<br>
isphenvl;<br>
(d)	a radical of substructure le<br><br>
which is bound to the molecule via the nitrogen atom, wherein<br>
R27 is alkyl or alkyl carbonyl and R28 is hydrogen, alkoxy or halogen; or<br>
(e)	NR^R^, wherein R2o and R21 are independently selected from hydrogen, alkyl,<br>
cycloalkyl which is unsubstituted or mono- or disubstituted by hydroxy; and phenyl which<br>
is unsubstituted or mono- or disubstituted by 1,2,3-thiadiazolyl, under the proviso that not<br>
both R^ and R2i can represent hydrogen at the same time; and<br>
R2 denotes alkyl, which is unsubstituted or substituted by cycloalkyl which is unsubstituted or mono- or disubstituted by halogen; or phenyl, which is mono- or disubstituted by halogen;<br>
under the proviso that R2 does not represent 1,1-dimethylethyl, if<br>
(a) Ri is benzo[b]imidazol-1-yI, 1-imidazolyI, 4,5-dichloro-1-imidazolyl, a-fC^alkylJ-l-imidazolyl, imidazolidin-2,5-dion-1-yl, 5,5-dimethyl-oxazolidin-2,4-dion-3~yl, 1H-1,2,3-triazol-1-yl, 2H-1,2,3-triazol-2-yl&gt; 3-nitro-1H-1,2,4-triazoM-yl, 2H-tetrazol-2-yl or 1H-tetrazol-1-yl, or if Ri is a radical of substructure Ic, R23 to R26 are hydrogen, X is NR18 and R18 is hydrogen, methyl, ethyl, acetyl, 4-pyridyl, 1-piperidinyl, phenyl, methoxyphenyl, ethoxyphenyl, fluorophenyl or chlorophenyl;<br><br>
(b)	Ri is a radical of substructure lcF R23 to R&amp; are hydrogen, X is -(CH2)S-CR17R18~, s is 0, and R17 and R18 are selected from hydroxyl and phenyl which is monosubstituted by chloro or R17 and R18 are selected from hydrogen, methoxyphenyl and N-phenyl-carbamoyl; or<br>
(c)	Ri is a radical of substructure Id, k is 1, A is a bond, E is NR22, R22 is hydrogen, G, Q and T are CH2, B and D are carbonyl and R19 is methyl, n-propyl or iso-butyl;<br>
under the proviso that R2 does not represent 2-methylpropyl, if Ri is a radical of substructure Id, k is 1, A is a bond, E is NR22, R^ is hydrogen, G, Q and T are CH2, B and D are carbonyl and R19 is methyl, or if Ri is a radical of substructure Ic, R23 to R26 are hydrogen, X is -(CH2)s-CR17Ri8-» s is 0, and R17 and R18 are selected from hydrogen and phenyl which is monosubstituted hy methoxy;<br>
i<br>
and under the proviso that R2 does not represent 1-methylethyl, if Rt is a radical of substructure Ic, R23 to R26 are hydrogen, X is NR18 and R18 is methoxyphenyl or ethoxyphenyl, orX is CR17R18 and R17 and R18 are selected from hydrogen and methoxyphenyl;<br>
or an N-oxide or a tautomer thereof,<br>
or a salt of such pyrrolo pyrimidine, its N-oxide or its tautomer.<br>
2. A pyrrolo pyrimidine of formula I according^ to claim 1, wherein<br>
Y represents -CH2-0- or -CH2-S-,<br>
pis 1,<br>
Ri represents<br>
(0) phenyl which is unsubstituted or mono- or disubstituted by<br>
(a) halogen, carboxy, CrC4alkoxy, nitro, CrC4alkyl-C(0)-NH-, C3-C4cycloalkyl-C(0)-NH-, Ci-C4alkyl-C(0)-N(CrC4alkyl)-, formyl, d-Gjalkyl-C^O)-, CrC4alkyl-S(0)2-NH-f CFs-CrCaalkyl-SCOVNH-, 1-pyrrolidinyl-carbonyl, 1-piperidinyl-carbonyl, 4-morpholinyl-carbonyl, 4-(CrC4alkyl)-1-piperazinyl carbonyl, 4-piperidinyl, 1-piperidinyl, l-CCi-C^lkyl-carbonylH-piperidinyl, 1f2,3,6-tetrahydro-4-pyridyl, 1-(Cr C4alkyl-carbonyl)-1,2,3,6-tetrahydro-4-pyridyl, 1-piperazinyl, 4-(CrC4alkyl)-1-piperazinyl, 4-(CrC4alkyl-carbonyl)-1 -piperazinyl, 4-(C3-C5cycloalkyl-carbonyl)-1-piperazinyl, 4-(C1-C4alkoxy-carbonyl)-1 -piperazinyl, 4-(CrC4alkyl-S02)-1 -piperazinyl,<br><br>
1,4-diazacyclohept-1 -yl, 4-(CrC4alkyl-carbonyl)-1,4-diazacyclohept-1 -yl, 2-oxo-1 -Ryrrolidinyl,3&gt;3-di-(CrC4alkyl)-2-oxo-1-pyrrolidinyl;<br>
(P) R3-CrC4alkyl, wherein R3 represents hydrogen, hydroxyl, carboxy, Ci-C4alkyl-N(CrC4alky!)-, CrC4alkyl-NH-, 1-pyrrolidinyl, 1-piperidyl, 4-(CrC4alkyl)-1-piperazinyl carbonyl, 2f4-dioxa-5l5-(di-CrC4alkyl)-oxa2olJdin-3-yl&gt; RiRsN-CKO)-, wherein R4 and R5 independently of each other represent hydrogen or CrC4alkyl; or (y) ReR7N-C(0)-, wherein R6 and R7 independently of each other represent hydrogen, CrC4alkyl, C5-C7cycloalkyl-CrC4aIkyl, CF3-CrC3alkyl or pyridyl-CrC4alkyl; (p) pyridyl, which is unsubstituted or mono- or disubstituted by halogen or CrC4aIkyI<br>
which is di- or trisubstituted by halogen; (q) pyrimidyl;<br>
(r) indolyl, which is monosubstituted by CrC4alkyl-C(0)-NH-CrC4alkyl; (s) Z-CCrC^lkyO-benzothiazolyl; (t) a radical of subformula la<br>
wherein R&amp; is hydrogen, R9 is hydrogen, and m is 2 or 3; or (u) a radical of subformula lb<br>
wherein Rio is hydrogen, Rn is hydrogen, and n is 2 or 3; R2 represents Ci-Csalkyl, which is unsubstituted or substituted by Cs-Cycycloalkyl, which is unsubstituted or disubstituted by halogen, or phenyl, which is mono- or disubstituted by halogen; under the proviso that R2 does not represent 1,1-dimethylethyl if Y is O and R, is selected from 3-pyridyl, 4-pyridyl, 5-chlon&gt;3-pyridyl, 6-chloro-3-pyridyl, 2-chloro-4-pyridyl&gt; 2-trifluoromethyl-4-pyridyl, 2-difluoromethyl-4-pyridylf 4-acetyH-piperazinyl-phenyl, 4-methyl-1-piperazinyl-methyl-phenylf and under the proviso that R2 does not represent 1,1-dimethylethyl, if Y is S and R1 is 4-pyridyl; or<br>
Y is CH2 or -CH=CH-, p is 1 or 2, -Ri represents<br>
(e)	thienyl, thiazolyl, 1-piperidinyl-carbonyl, or<br>
(f)	phenyl which is unsubstituted or mono- or disubstituted by<br>
(i) CrC4alkoxy, H2N-C(0)-, 4-(CrC4alkyl-carbonyl)-1-piperazinyl, 2-oxo-1-pyrrolidinyl, or halogen;<br><br>
(ii) Ri2-0-C(0)-, wherein Ri2is hydrogen or CrC4alkylf or<br>
(iji) Ri3NH-f wherein Ri3 represents hydrogen or a radical Ri4-CrC4alkyl-Z-, wherein Z is CO or S02 and R14 denotes hydrogen, trifluoromethyl or CrC4alkoxy, (Iv) Ri5-C1-C4alkyl, wherein R15 denotes hydrogen, hydroxy, lower alkoxy, 1-pyrrolidinyl, 2-oxo-1-pyrroIidinyl, imidazolidin-2,5-dion-1-yl, 5,5-dimethyl-oxazolidin-2,4-dion-3-yl or CrC4alkyl-N(R16)-, wherein R10 represents hydrogen or CrC4alkyl; and R2 represents<br>
(a)	CrCyalkyl, which is unsubstituted or substituted by C2-C3alkenylf indanyl, C3-C7cycloalkyl which is unsubstituted or disubstituted by halogen or Ci-C4alkylv C3-C/cycloalkenyl, phenyl, which is unsubstituted or moro- or disubstituted by halogen or by Ci-C4alkyl;<br>
(b)	QrCycycloalkyl; or<br>
(c)	d*-C4alkylcarbonyI;<br>
under the proviso that, if Y is CH2, Ri represents 4-chlorophenyl and p is 1, R2 does not denote 1,1-dimethylethyI, 1-methylethyl, cyclopropyl, cyclohexyl, 2-methyl-propyl or 2-ethyl-propyl;<br>
under the proviso that R2 does not represent 1,1-dimethylethyl, if p is 1, Y is CH2 and R^ represents thienyl, phenyl, methoxyphenyl, propoxyphenyl, 4-fluorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-butylphenyl, hydroxymethylphenyl, 4-(5,5-dimethyl-oxazolidin-2,4-dion-3-yl-methyl)-phenyl, 4-(methylsulfonylamino)-phenyl, 4-(n-butyl-sulfonylamino)-phenyl, 4-(ethylsulfonylamino)-phenyl,4-(n-propylsulfonylamino)-phenylf 4-(iso-propylsulfonylamino)-phenyl, 4-aminophenyl, 4-(acetylamino)-phenyl, 4-(butanoylamino)-phenyl or 4-(diethylaminomethyl)-phenyl;<br>
and under the proviso that that R2 does not represent 1-methylethyl, if p is 1, Y is CH2 and Ri represents phenyl which is unsubstituted or substituted by 4-acetyI-1-piperazinyl; or<br>
Y is CH2,<br>
p is 1,<br>
Ri represents<br>
(a) 1,2,3,6-tetrahydropyrid-1-yl, 4-(CrC4alkyl)-1,2f3,6-tetrahydropyrid-1-yl, 4,5-di(Cr C4a!kyl)-1,2,3,6-tetrahydropyrid-1-yl, 5-chloro-1,2,3f6-tetrahydropyrid-1-yl,4-phenyl-1,2,3,6-tetrahydropyrid-1-yl, Inmidazolyl, 2-(CrC4alkyl)-1-imidazolylf 4,5-dihalo-1-imidazolyl, imidazolidin-2,5<jion-1-yl></jion-1-yl><br>
imidazolidin-2,5-dion-1 -yl, 3-trifluoromethyl-3,4-pyrrolin-1 -yl, 1 -pyrrolidinyl, 3-CrC4alkyl-1 -pyrrolidinyl, 3f3-di-(CrC4alkyl)-1-py.rrolidinyl, 3-CrC4alkoxy-1 -pyrrolidinyl, 3-C1-C4alkyl-2-oxo-1-pyrrolidinyl, 3,3"di-(C1-C4alkyl)-2-oxo-1-pyrrolidinyl, 3-halo-1 -pyrrolidinyl, 3,3-di-halo-1-pyrrolidinyl, 3,3-di-ha!o-1-piperidinyl, 1H-1,2,3-triazoM-yl, 2H-1,2f3-triazol-2-yl, 1H-1,2f4-triazol-1-yl, 3-nitro-1H-1,2,4-triazoi-1-yl, 2-phenyM-imidazolyl, 2H-tetrazol-2-yl, 1H-tetrazol-1 -yl, benzo[b]imidazol-1 -yl, 3-(1 -(C1-C4alkyl-S02)-4-piperidinyl)-2l3-dihydro-2-oxo-benzo[b]imidazol-1-yl, 3-(1-CrC4alkylcarbonyl-4-piperidinyl)-2,3-dihydro-2»oxo-benzo[b]imidazoM-yl, 1-indolyI, 6-halo-1-indolyl, 1,3-dihydro-2-isoindolyl, 2,3-dihydro-1-indolyl, 2,3-dihydro-2-oxo-benzo[b]thiazol-3yl, 6f7-di-(CrC4alkoxy)-1,2,3,4-tetrahydroquinnolin, 6-CrC4alkoxy-1,2,3,4-tetrahydroisoquinnolin, 7-CrC4alkoxy-1,2,3,4-tetrahvdroisoquinnolin;<br>
(b)	a radical of substructure Ic<br>
which is bound to the molecule via the nitrogen atom, wherein<br>
X is -©-, -(CH2)S-CR17RIB- or -NR18, wherein<br>
s is 0 or 1, R17 and R18 are independently selected from hydrogen, halogen, hydroxy, d-<br>
C4alkyl, phenyl-CrC4alkyl-carbonyl, carbamoyl, N-phenyl-carbamoyl, cyano, 4-pyridyl, 1-<br>
piperidinyl and phenyl which is unsubstituted or monosubstituted by halogen or Cr<br>
C4alkoxy, or, if X is CR17R1B) R17 and R18 and together form an oxo group or a group HO-<br>
C(0)-CH=, and<br>
R23, R24, R25 and R26 are independently selected from hydrogen and CrC4alkyl;<br>
(c)	a radical of substructure Id<br>
which is bound to the molecule via the nitrogen atom, wherein k is 0 or 1, A is CH2 or a bond, B is CH2 or carbonyl, D is CH2 or carbonyl, E is CH2 or NR^, G is CH2 or a bond, Q is CH2 or carbonyl, T is CH2 or NR29, R19 represents hydrogen, CrC4alkyl, phenyl-d-C4alkyl, CrC4alkylcarbonyl or CrC4alkyl-S02-, R^ is hydrogen and R29 is phenyl;<br>
(d)	a radical of substructure le<br>
which is bound to the molecule via the nitrogen atom, wherein<br>
R27 is CrC4alkyl or CrC4alkylcarbonyl and R28 is hydrogen, Ci-C4alkoxy or halogen; or<br>
(e)	NR20R2i, wherein R20 and R2? are independently selected from hydrogen, CrC4alkyI,<br>
C3-C7cycloalkyl which is unsubstituted or monosubstituted by hydroxy; and phenyl which<br>
is unsubstituted or monosubstituted by 1,2,3-thiadiazol-4-yl, under the proviso that not<br>
both R20 and R21 can represent hydrogen at the same time; and<br><br>
R2 denotes Ci-C8alkyl, which is unsubstituted or substituted by C3-C7cycloalkyi which is unsubstituted or disubstituted by halogen; phenyl, which is mono- or disubstituted by halogen;  .<br>
under the proviso that R2 does not represent 1,1-dimethyIethyl, if<br>
(a)	Ri is benzo[b]imidazol-1-yl, 1-imidazolyl, 4f5-dichloro-1-imidazolyl, 2-(CrC4alkyl)-1-imidazolyl, imidazolidin-2,5-dion-1-yl, 5,5-dimethyl-oxazoIidin-2,4-dion-3-yl, 1H-1,2,3-triazol-1-yl, 2H-1,2,3-triazol-2-yl, S-nitro-IH-l^-triazoM-yl, 2H-tetrazol-2-yl or 1H-tetrazol-1-yl, or if Rt is a radical of substructure lc, R23 to R26 are hydrogen, X is NR18 and RIB is hydrogen, methyl, ethyl, acetyl, 4-pyridyi, 1-piperidinyl, phenyl, methoxyphenyl, ethoxyphenyl, fluorophenyl or chlorophenyl;<br>
(b)	R, is a radical of substructure !c, R2S to R23 aro hydrogen, X Is -(r-H2}s CRi7R*B-i * is 0, and R17 and Ri8 are selected from hydroxyl and phenyl which is monosubstituted by chloro or Ri7 and R18 are selected from hydrogen, methoxyphenyl and N-phenyl-carbarnoyl; or<br>
(c)	Ri is a radical of substructure Id, k is 1, A is a bond, E is NR^, R22 is hydrogen, G, Q and T are CH2, B and D are carbonyl and R19 is methyl, n-propyl or iso-butyl;<br>
under the proviso that R2 does not represent 2-methylpropyl, if R^ is a radical of substructure Id, k is 1, A is a bond, E is NR22, R22 is hydrogen, G, Q and T are CH2, B and D are carbonyl and R19 is methyl, or if Ri is a radical of substructure lc, R23 to R26 are hydrogen, X is "(CH2)S-CR17R18-, s is 0, and Ri7 and R18 are selected from hydrogen and phenyl which is monosubstituted by methoxy;<br>
and under the proviso that R2 does not represent 1-methyiethyl, if R1 is a radical of substructure lc, R23 to R26 are hydrogen, X is NRi8 and R18 is methoxyphenyl or ethoxyphenyl, or X is CRi7R18 and R17 and R?8 are selected from hydrogen and methoxyphenyl;<br>
or a tautomer thereof,<br>
or a salt of such pyrrolo pyrimidine or its tautomer.<br>
♦3. A pyrrolo pyrimidine of formula I according to claim 1 or 2, or an N-oxide or a tautomer thereof, or a pharmaceutical^ acceptable salt of such a compound, for use in a method for the treatment of the human or animal body.<br><br>
4.	Use of a pyrrolo pyrimidine of formula I according to claim 1 or 2, or an N-oxide or a tautomer thereof, or a pharmaceutically acceptable salt of such a compound, for the preparation of a pharmaceutical product for the treatment of neuropathic pain.<br>
5.	A method for the treatment of neuropathic pain, which comprises administering a pyrrolo pyrimidine of formula I according to claim 1 or 2, or a N-oxide or a tautomer thereof, or a pharmaceutically acceptable salt thereof, its N-oxide or its tautomer, in a quantity effective against said disease, to a warm-blooded animal requiring such treatment.<br>
6.	A pharmaceutical preparation, comprising a pyrrolo pyrimidine of formula I according to claim t or 2, or an N-oxide or a tautomer thereof, or a pharmaceutically acceptable salt of such a compound, or a hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier.<br>
7.	A process for the preparation of a pyrrolo pyrimidine of formula I<br><br>
wherein Y represents -(CH2)rO- or (CH2)r-S-<br>
p is 1 or 2,<br>
ris 1,2 or 3,<br>
tis1,2or3,<br>
fy represents<br>
(v) phenyl which is unsubstituted or mono-, di- or trisubstituted by<br>
(a) halogen, carboxy, alkoxy, nitro, alkyl-C(0)-NH-, cycIoaIkyl-G(0)-NH-, alkyl-C(O)-N(alkyl)-( formyl, alkyl-C(O)-, alkyl-S(0)2-NH-t CF3-alkyl-S(0)2-NH-f pyrrolidinyl carbonyl, piperidinyl carbonyl, morpholinyl carbonyl, N-alkyl piperazinyl carbonyl, piperidinyl, 1-(alkyl carbonyl) piperidinyl, 1,2,3,6-tetrahydropyridyl, alkyl carbonyl 1,2,3,6-tetrahydropyridyl, piperazinyl, alkyl piperazinyl, alkyl carbonyl piperazinyl, cycloalkyl carbonyl piperazinyl, alkoxy carbonyl piperazinyl, alkyl-S02-plperazinyl, diazacycloheptyl, alkyl carbonyl diazacycloheptyl, 2-oxo-1 -pyrrolidinyl, 3,3-di-alkyl-2-<br><br>
oxo-1-pyrrolidinyl;<br>
(P) fValkyl, wherein R3 represents hydrogen, hydroxy, carboxy, alkyl-N(alkyl)-, alkyl-<br>
NH-, 1-pynrolidinyl, 1-piperidyl, 4-aikyl-1-piperazinyl carbonyl, 2,4-dioxa-5,5-(di-alkyl)-<br>
oxazolidin-3-yl, R4R5N-C(0)-, wherein R4 and R5 independently of each other<br>
represent hydrogen or alkyl; or<br>
(y) ReR7N-C(0)-( wherein R6 and R7 independently of each other represent hydrogen,<br>
alkyl, cycloalkyl alkyl, CF3-alkyl or pyridyl alkyl; (w) pyridyl, which Is unsubstituted or mono-, di- or trisubstituted by halogen or alkyl which<br>
is mono-, di- or trisubstituted by halogen; (x) pyrimidyl;<br>
(y) »ndolyl, which is mono- or disubstituted by aIkyl-C(0)-NH-a!kyl;. (z) 2-(alkyl)-benzothiazolyl; (aa)     a radical of subformula la<br><br>
wherein R8 is hydrogen, halogen or alkyl, R9 is hydrogen or alkyl, and m is 1, 2, 3 or 4; or (bb)     a radical of subformula lb<br><br>
wherein Rio is hydrogen, halogen or alkyl, Rn is hydrogen or alkyl, and n is 1,2, 3 01<br>
4; R2 represents alkyl, which is unsubstituted or substituted by cycloalkyl, which is unsubstituted or mono- or disubstituted by halogen, or phenyl, which is mono- or disubstituted by halogen;<br><br>
under the proviso that R2 does not represent 1,1-dimethylethyl if Y is O and fy is selected from 3-pyridyl, 4-pyridyl, 5-chloro-3-pyridyl, 6-chloro-3-pyridyl, 2-chloro-4-pyridyl, 2-trifIuoromethyl-4-pyridyI, 2-difluoromethyl-4-pyridyl, 4-acetyM-piperazinyl-phenyl, 4-methyl-1 -piperazinyl-methyl-phenyl, and<br>
under the proviso that R2 does not represent 1,1-dimethylethyl, if Y is S and Ri is 4-pyridyl;<br>
wherein an alcohol or a thiol of formula llv<br>
Rr(Y)p-H	(II)<br>
wherein Y represents -(CH2)rO- or (CH2)rS- and t, r and R^ have the meanings as provided above for a compound of formula I, is alkylated with a pyrrolp pyrimidine of formula Si I<br><br>
wherein R2 has the meaning as provided above for a compound of formula I and Hal denotes halo, preferably bromo,<br>
wherein the starting compounds of formula II and III may also be present with functional groups in protected form, if necessary, and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible;<br>
wherein any protecting groups in a protected derivative of a compound of the formula I are removed;<br>
and, if so desired, an obtainable compound of formula I is converted into another compound of formula I or a N-oxide thereof, a free compound of formula I is converted into a salt, an obtainable salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
CLAIMS:<br>
1. A pyrrolo pyrimidine of formula I,<br><br>
wherein<br>
Y represents -(CH2)rO- or -(CH2)rS-,<br>
p is 1 or 2,<br>
ris 1,2 or 3,<br>
t is 1,2 or 3,<br>
R1 represents<br>
(h) phenyl which is unsubstituted or mono-, di- or trisubstituted by<br>
(a) halogen, carboxy, alkoxy, nitro, alkyl-C(0)-NH-, cyc!oalkyl-C(0)-NH-, alkyl-C(O)-N(alkyl)-, formyl, alkyl-C(O)-, alkyl-S(0)2-NH-, CF3-alkyl-S(0)2-NH-, pyrrolidinyl carbonyl, piperidinyl carbonyl, morpholinyl carbonyl, N-alkyl piperazinyl carbonyl, piperidinyl, 1-(alkyl carbonyl) piperidinyl, 1,2,3,6-tetrahydropyridyl, alkyl carbonyl 1,2,3,6-tetrahydropyridyl, piperazinyl, alkyl piperazinyl, alkyl carbonyl piperazinyl, cycloalkyl carbonyl piperazinyl, alkoxy carbonyl piperazinyl, alkyl-S02-piperazinylf diazacycloheptyl, alkyl carbonyl diazacycloheptyl, 2-oxo-1-pyrrolidinyl, 3,3-di-alkyl-2-oxo-1-pyrrolidinyl;<br>
(P) R3-alkyl, wherein R3 represents hydrogen, hydroxy, carboxy, alkyl-N(alkyl)-, all^yl-NH-, 1-pyrrolidinyl, 1-piperidyl, 4-alkyl-1-piperazinyl carbonyl, 2,4-dioxa-5,5-(di-alkyl)-oxazolidin-3-yl, R4R5N-C(0)-, wherein R4 and R5 independently of each other represent hydrogen or alkyl; or<br>
(y) RaR7N-C(0)-, wherein R6 and R7 independently of each other represent hydrogen, alkyl, cycloalkyl alkyl, CF3-alkyl or pyridyl alkyl; (i) pyridyl, which is unsubstituted or mono-, di- or trisubstituted by halogen or alkyl which<br>
is mono-, di- or trisubstituted by halogen; (j) pyrimidyl;<br><br>
(k) indoiyl, which is mono^ or disubstituted by alkyl-C(0)-NH-alkyl; (I) 2-(alkyl)-benzothiazolyl; (m)a radical of subformula la<br><br>
wherein Ra IS hydrogen, halogen or alkyl, R9 is hydrogen or alkyl, and m h 1, 2, 3 or 4; or (n) a radical of subformula lb<br><br>
wherein R10 is hydrogen, halogen or alkyl, Rn is hydrogen or alkyl, and n is 1,2, 3 or 4; R2 represents alkyl, which is unsubstituted or substituted by cycloalkyl, which is<br>
unsubstituted or mono- or disubstituted by halogen, or phenyl, which Is mono- or<br>
disubstituted by halogen; under the proviso that R2 does not represent 1,1-dimethylethyl if Y is O and R^ is selected<br>
from 3-pyridyl, 4-pyrldyl, 5-chioro-3-pyridyl, 6-chloro-3-pyridyl, 2-chloro-4-pyridyl, 2-<br>
trifluoromethyl-4-pyridyl, 2-difluoromethyl-4-pyridyl, 4-acetyl-1-piperazinyl-phenyl, 4-<br>
methyl-1-piperazinyl-methyl-phenyl,and under the proviso that R2 does not represent 1,1-dimethylethyl, if Y is S and Ri is 4-pyridyl;<br>
or<br>
Yis^CH2)ror-~CH=CH-,<br>
jis1or2;<br>
p is 1 or 2,<br><br>
Ri represents<br>
(c)	thienyl, thiazolyl, 1-piperidinyl-carbonyl, or<br>
(d)	phenyl which is unsubstituted or mono-, di- or trisubstituted by<br>
(i) alkoxy, H2N-C(0)-, 4-(alkyl carbonyl) 1-piperazinyl, 2-oxo-1-pyrrolidinyl, or<br>
halogen;<br>
(ii) Ri2-0-C(0)-t wherein Ri2is hydrogen or alkyl, or<br>
(iii) R13NH-, wherein R13 represents hydrogen or a radical R14-alkyl-Z-, wherein Z is<br>
CO, SO or S02 and R14 denotes hydrogen, trifluoromethyl or alkoxy,<br>
(iv) Ri5-alkyl, wherein R15 denotes hydrogen, hydroxy, lalkoxy, 1-pyrrolidinyl, 2-oxo-1-<br>
pyrrolidinyl, imidazolidin-2,5-dion-1-yl, 5,5-di-alkyI-oxazolidin-2,4-dion-3-yl or alkyl-<br>
M(R™)-&gt; wherein Ri6 represents hydrogen or alkyi; and<br>
•'* ■■■!i-     ..-•■■■■■■■.-■<br>
R2 represents<br>
(a)	alkyl, which is unsubstituted or substituted by alkenyl, indanyl, cycloalkyl which is unsubstituted or mono- or disubstituted by halogen or alkyl, cycloalkenyl, phenyl, which is unsubstituted or mono- or disubstituted by halogen or by alkyl;<br>
(b)	cycloalkyl; or<br>
(c)	alkylcarbonyl;<br>
under the proviso that, if Y is CH2) Ri represents 4-chlorophenyl and p is 1, R2 does not denote 1,1-dimethylethyl, 1-methylethyl, cyclopropyl, cyclohexyl, 2-methyl-propyl or 2-ethyl-propyl;<br>
under the proviso that R2 does not represent 1,1-dimethylethyl, if p is 1, Y is CH2 and R, represents thienyl, phenyl, methoxyphenyl, propoxyphenyl, 4-fluorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-butylphenyl, hydroxymethylphenyl, 4-(5,5-dimethyl-oxazolidin-2,4-dion-3-yl-methyl)-phenylf 4-(methylsulfonylamino)-phenyl,4-(n-butyl-sulfonylamino)-phenyl, 4-(ethylsulfonylamino)-phenyl, 4-(n-propyIsulfonylamino)-phenyl, 4-(iso-propylsulfonylamino)-phenyl, 4-aminophenyl, 4-(acetylamino)-phenyl, 4-(butanoylamino)-phenyl or 4-(diethylaminomethyl)-phenyl;<br>
and under the proviso that that R2 does not represent 1-methylethyl, if p is 1, Y is CH2 and Ri represents phenyl which is unsubstituted or substituted by 4-acetyl-1-piperazinyl; or<br>
Y is -<ch2></ch2>
fis1or2;<br>
pis1f<br><br>
Ri represents<br>
(a)	1,2,3,6-tetrahydropyrkM-yl, alW-1.2,3,6-tetrahydropyrid-1-ylf di-alkyl-1,2,3,6-tetrahydropyrid-1-yl, halo-1,2,3,6-tetrahydropyrid-1-yl, phenyl-1,2,3,6-tetrahydropyrid-1-yl, imidazolyl, alkyl imidazolyl, di-halo imidazolyl, imidazolidin-2,5-dion-1-yl, 5,5-dilalkyl-oxazolidin-2,4-dion-3-yl, alkyl imidazolidin-2,5-dion-1-yl, trifluoromethyl-3,4-pyrrolin-1-yl, pyrrolidinyl, alkyl 1-pyrrolidinyl, di-alkyl) pyrrolidinyl, alkoxy pyrrolidinyl, alkyl 2-oxo-1-pynrolidinyl, di-alkyl 2-oxo-1-pyrrolidinyl, halo 1-pyrrolidinyl, di-halo 1-pyrrolidinyl, di-halo 1-piperidinyl, triazolyl, nitro triazolyl, phenyl imidazolyl, tetrazolyl, benzo[b]imidazolyl, (1-(alkyl-S02)-4-piperidinyl)-2,3-dihydro-2-oxo-benzo[b]imidazolyl, 3-(alkyl carbonyl-4-piperidinyl)-2,3-dihydro-2-oxo-benzo[b]imidazolylt indolyl, halo 1-indolyl, 1,3-dihydro-2-isoinddlyl, 2,3-dihydro-1-indolyl, 2,3-dlhydro-2-oxo-benzo[b]thiazolyl, di-alkoxv 1,2,3,4-tetrahydroquinnolin, alkoxy-1,2,3,4-tetrahydroisoquinnolin;<br>
(b)	a radical of substructure Ic<br><br>
which is bound to the molecule via the nitrogen atom, wherein<br>
X is -0-, -(CH2)s-CRi7Rie- or -NR18, wherein<br>
s is 0,1 or 2, R17 and R18 are independently selected from hydrogen, halogen, hydroxy,<br>
alkyl, phenyl alkyl carbonyl, carbamoyl, N-phenyl carbamoyl, cyano, pyridyl, piperidinyl<br>
and phenyl which is unsubstituted or mono- or disubstituted by halogen or alkoxy, or, if X<br>
is CR|7R18, Ri7 and R18 and together form an oxo group or a group HO-C(0)-CH=, and<br>
R23t R24, R25 and R26 are independently selected from hydrogen and alkyl;<br>
(c)	a radical of substructure Id<br><br><br>
which is bound to the molecule via the nitrogen atom, wherein<br>
k is 0,1 or 2, A is CH2 or a bond, B is CH2 or carbonyl, D is CH2 or carbonyl, E is CH2 or<br>
NR^, G is CH2 or a bond, Q is CH2 or carbonyl, T is CH2 or NR29, R19 represents<br>
hydrogen, alkyl, phenyl alkyl, alkyl carbonyl or alkyl-S02-f R^ is hydrogen or alkyl and R29<br>
isphenvl;<br>
(d)	a radical of substructure le<br><br>
which is bound to the molecule via the nitrogen atom, wherein<br>
R27 is alkyl or alkyl carbonyl and R28 is hydrogen, alkoxy or halogen; or<br>
(e)	NR^R^, wherein R2o and R21 are independently selected from hydrogen, alkyl,<br>
cycloalkyl which is unsubstituted or mono- or disubstituted by hydroxy; and phenyl which<br>
is unsubstituted or mono- or disubstituted by 1,2,3-thiadiazolyl, under the proviso that not<br>
both R^ and R2i can represent hydrogen at the same time; and<br>
R2 denotes alkyl, which is unsubstituted or substituted by cycloalkyl which is unsubstituted or mono- or disubstituted by halogen; or phenyl, which is mono- or disubstituted by halogen;<br>
under the proviso that R2 does not represent 1,1-dimethylethyl, if<br>
(a) Ri is benzo[b]imidazol-1-yI, 1-imidazolyI, 4,5-dichloro-1-imidazolyl, a-fC^alkylJ-l-imidazolyl, imidazolidin-2,5-dion-1-yl, 5,5-dimethyl-oxazolidin-2,4-dion-3~yl, 1H-1,2,3-triazol-1-yl, 2H-1,2,3-triazol-2-yl&gt; 3-nitro-1H-1,2,4-triazoM-yl, 2H-tetrazol-2-yl or 1H-tetrazol-1-yl, or if Ri is a radical of substructure Ic, R23 to R26 are hydrogen, X is NR18 and R18 is hydrogen, methyl, ethyl, acetyl, 4-pyridyl, 1-piperidinyl, phenyl, methoxyphenyl, ethoxyphenyl, fluorophenyl or chlorophenyl;<br><br>
(b)	Ri is a radical of substructure lcF R23 to R&amp; are hydrogen, X is -(CH2)S-CR17R18~, s is 0, and R17 and R18 are selected from hydroxyl and phenyl which is monosubstituted by chloro or R17 and R18 are selected from hydrogen, methoxyphenyl and N-phenyl-carbamoyl; or<br>
(c)	Ri is a radical of substructure Id, k is 1, A is a bond, E is NR22, R22 is hydrogen, G, Q and T are CH2, B and D are carbonyl and R19 is methyl, n-propyl or iso-butyl;<br>
under the proviso that R2 does not represent 2-methylpropyl, if Ri is a radical of substructure Id, k is 1, A is a bond, E is NR22, R^ is hydrogen, G, Q and T are CH2, B and D are carbonyl and R19 is methyl, or if Ri is a radical of substructure Ic, R23 to R26 are hydrogen, X is -(CH2)s-CR17Ri8-» s is 0, and R17 and R18 are selected from hydrogen and phenyl which is monosubstituted hy methoxy;<br>
i<br>
and under the proviso that R2 does not represent 1-methylethyl, if Rt is a radical of substructure Ic, R23 to R26 are hydrogen, X is NR18 and R18 is methoxyphenyl or ethoxyphenyl, orX is CR17R18 and R17 and R18 are selected from hydrogen and methoxyphenyl;<br>
or an N-oxide or a tautomer thereof,<br>
or a salt of such pyrrolo pyrimidine, its N-oxide or its tautomer.<br>
2. A pyrrolo pyrimidine of formula I according^ to claim 1, wherein<br>
Y represents -CH2-0- or -CH2-S-,<br>
pis 1,<br>
Ri represents<br>
(0) phenyl which is unsubstituted or mono- or disubstituted by<br>
(a) halogen, carboxy, CrC4alkoxy, nitro, CrC4alkyl-C(0)-NH-, C3-C4cycloalkyl-C(0)-NH-, Ci-C4alkyl-C(0)-N(CrC4alkyl)-, formyl, d-Gjalkyl-C^O)-, CrC4alkyl-S(0)2-NH-f CFs-CrCaalkyl-SCOVNH-, 1-pyrrolidinyl-carbonyl, 1-piperidinyl-carbonyl, 4-morpholinyl-carbonyl, 4-(CrC4alkyl)-1-piperazinyl carbonyl, 4-piperidinyl, 1-piperidinyl, l-CCi-C^lkyl-carbonylH-piperidinyl, 1f2,3,6-tetrahydro-4-pyridyl, 1-(Cr C4alkyl-carbonyl)-1,2,3,6-tetrahydro-4-pyridyl, 1-piperazinyl, 4-(CrC4alkyl)-1-piperazinyl, 4-(CrC4alkyl-carbonyl)-1 -piperazinyl, 4-(C3-C5cycloalkyl-carbonyl)-1-piperazinyl, 4-(C1-C4alkoxy-carbonyl)-1 -piperazinyl, 4-(CrC4alkyl-S02)-1 -piperazinyl,<br><br>
1,4-diazacyclohept-1 -yl, 4-(CrC4alkyl-carbonyl)-1,4-diazacyclohept-1 -yl, 2-oxo-1 -Ryrrolidinyl,3&gt;3-di-(CrC4alkyl)-2-oxo-1-pyrrolidinyl;<br>
(P) R3-CrC4alkyl, wherein R3 represents hydrogen, hydroxyl, carboxy, Ci-C4alkyl-N(CrC4alky!)-, CrC4alkyl-NH-, 1-pyrrolidinyl, 1-piperidyl, 4-(CrC4alkyl)-1-piperazinyl carbonyl, 2f4-dioxa-5l5-(di-CrC4alkyl)-oxa2olJdin-3-yl&gt; RiRsN-CKO)-, wherein R4 and R5 independently of each other represent hydrogen or CrC4alkyl; or (y) ReR7N-C(0)-, wherein R6 and R7 independently of each other represent hydrogen, CrC4alkyl, C5-C7cycloalkyl-CrC4aIkyl, CF3-CrC3alkyl or pyridyl-CrC4alkyl; (p) pyridyl, which is unsubstituted or mono- or disubstituted by halogen or CrC4aIkyI<br>
which is di- or trisubstituted by halogen; (q) pyrimidyl;<br>
(r) indolyl, which is monosubstituted by CrC4alkyl-C(0)-NH-CrC4alkyl; (s) Z-CCrC^lkyO-benzothiazolyl; (t) a radical of subformula la<br>
wherein R&amp; is hydrogen, R9 is hydrogen, and m is 2 or 3; or (u) a radical of subformula lb<br>
wherein Rio is hydrogen, Rn is hydrogen, and n is 2 or 3; R2 represents Ci-Csalkyl, which is unsubstituted or substituted by Cs-Cycycloalkyl, which is unsubstituted or disubstituted by halogen, or phenyl, which is mono- or disubstituted by halogen; under the proviso that R2 does not represent 1,1-dimethylethyl if Y is O and R, is selected from 3-pyridyl, 4-pyridyl, 5-chlon&gt;3-pyridyl, 6-chloro-3-pyridyl, 2-chloro-4-pyridyl&gt; 2-trifluoromethyl-4-pyridyl, 2-difluoromethyl-4-pyridylf 4-acetyH-piperazinyl-phenyl, 4-methyl-1-piperazinyl-methyl-phenylf and under the proviso that R2 does not represent 1,1-dimethylethyl, if Y is S and R1 is 4-pyridyl; or<br>
Y is CH2 or -CH=CH-, p is 1 or 2, -Ri represents<br>
(e)	thienyl, thiazolyl, 1-piperidinyl-carbonyl, or<br>
(f)	phenyl which is unsubstituted or mono- or disubstituted by<br>
(i) CrC4alkoxy, H2N-C(0)-, 4-(CrC4alkyl-carbonyl)-1-piperazinyl, 2-oxo-1-pyrrolidinyl, or halogen;<br><br>
(ii) Ri2-0-C(0)-, wherein Ri2is hydrogen or CrC4alkylf or<br>
(iji) Ri3NH-f wherein Ri3 represents hydrogen or a radical Ri4-CrC4alkyl-Z-, wherein Z is CO or S02 and R14 denotes hydrogen, trifluoromethyl or CrC4alkoxy, (Iv) Ri5-C1-C4alkyl, wherein R15 denotes hydrogen, hydroxy, lower alkoxy, 1-pyrrolidinyl, 2-oxo-1-pyrroIidinyl, imidazolidin-2,5-dion-1-yl, 5,5-dimethyl-oxazolidin-2,4-dion-3-yl or CrC4alkyl-N(R16)-, wherein R10 represents hydrogen or CrC4alkyl; and R2 represents<br>
(a)	CrCyalkyl, which is unsubstituted or substituted by C2-C3alkenylf indanyl, C3-C7cycloalkyl which is unsubstituted or disubstituted by halogen or Ci-C4alkylv C3-C/cycloalkenyl, phenyl, which is unsubstituted or moro- or disubstituted by halogen or by Ci-C4alkyl;<br>
(b)	QrCycycloalkyl; or<br>
(c)	d*-C4alkylcarbonyI;<br>
under the proviso that, if Y is CH2, Ri represents 4-chlorophenyl and p is 1, R2 does not denote 1,1-dimethylethyI, 1-methylethyl, cyclopropyl, cyclohexyl, 2-methyl-propyl or 2-ethyl-propyl;<br>
under the proviso that R2 does not represent 1,1-dimethylethyl, if p is 1, Y is CH2 and R^ represents thienyl, phenyl, methoxyphenyl, propoxyphenyl, 4-fluorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-butylphenyl, hydroxymethylphenyl, 4-(5,5-dimethyl-oxazolidin-2,4-dion-3-yl-methyl)-phenyl, 4-(methylsulfonylamino)-phenyl, 4-(n-butyl-sulfonylamino)-phenyl, 4-(ethylsulfonylamino)-phenyl,4-(n-propylsulfonylamino)-phenylf 4-(iso-propylsulfonylamino)-phenyl, 4-aminophenyl, 4-(acetylamino)-phenyl, 4-(butanoylamino)-phenyl or 4-(diethylaminomethyl)-phenyl;<br>
and under the proviso that that R2 does not represent 1-methylethyl, if p is 1, Y is CH2 and Ri represents phenyl which is unsubstituted or substituted by 4-acetyI-1-piperazinyl; or<br>
Y is CH2,<br>
p is 1,<br>
Ri represents<br>
(a) 1,2,3,6-tetrahydropyrid-1-yl, 4-(CrC4alkyl)-1,2f3,6-tetrahydropyrid-1-yl, 4,5-di(Cr C4a!kyl)-1,2,3,6-tetrahydropyrid-1-yl, 5-chloro-1,2,3f6-tetrahydropyrid-1-yl,4-phenyl-1,2,3,6-tetrahydropyrid-1-yl, Inmidazolyl, 2-(CrC4alkyl)-1-imidazolylf 4,5-dihalo-1-imidazolyl, imidazolidin-2,5<jion-1-yl></jion-1-yl><br>
imidazolidin-2,5-dion-1 -yl, 3-trifluoromethyl-3,4-pyrrolin-1 -yl, 1 -pyrrolidinyl, 3-CrC4alkyl-1 -pyrrolidinyl, 3f3-di-(CrC4alkyl)-1-py.rrolidinyl, 3-CrC4alkoxy-1 -pyrrolidinyl, 3-C1-C4alkyl-2-oxo-1-pyrrolidinyl, 3,3"di-(C1-C4alkyl)-2-oxo-1-pyrrolidinyl, 3-halo-1 -pyrrolidinyl, 3,3-di-halo-1-pyrrolidinyl, 3,3-di-ha!o-1-piperidinyl, 1H-1,2,3-triazoM-yl, 2H-1,2f3-triazol-2-yl, 1H-1,2f4-triazol-1-yl, 3-nitro-1H-1,2,4-triazoi-1-yl, 2-phenyM-imidazolyl, 2H-tetrazol-2-yl, 1H-tetrazol-1 -yl, benzo[b]imidazol-1 -yl, 3-(1 -(C1-C4alkyl-S02)-4-piperidinyl)-2l3-dihydro-2-oxo-benzo[b]imidazol-1-yl, 3-(1-CrC4alkylcarbonyl-4-piperidinyl)-2,3-dihydro-2»oxo-benzo[b]imidazoM-yl, 1-indolyI, 6-halo-1-indolyl, 1,3-dihydro-2-isoindolyl, 2,3-dihydro-1-indolyl, 2,3-dihydro-2-oxo-benzo[b]thiazol-3yl, 6f7-di-(CrC4alkoxy)-1,2,3,4-tetrahydroquinnolin, 6-CrC4alkoxy-1,2,3,4-tetrahydroisoquinnolin, 7-CrC4alkoxy-1,2,3,4-tetrahvdroisoquinnolin;<br>
(b)	a radical of substructure Ic<br>
which is bound to the molecule via the nitrogen atom, wherein<br>
X is -©-, -(CH2)S-CR17RIB- or -NR18, wherein<br>
s is 0 or 1, R17 and R18 are independently selected from hydrogen, halogen, hydroxy, d-<br>
C4alkyl, phenyl-CrC4alkyl-carbonyl, carbamoyl, N-phenyl-carbamoyl, cyano, 4-pyridyl, 1-<br>
piperidinyl and phenyl which is unsubstituted or monosubstituted by halogen or Cr<br>
C4alkoxy, or, if X is CR17R1B) R17 and R18 and together form an oxo group or a group HO-<br>
C(0)-CH=, and<br>
R23, R24, R25 and R26 are independently selected from hydrogen and CrC4alkyl;<br>
(c)	a radical of substructure Id<br>
which is bound to the molecule via the nitrogen atom, wherein k is 0 or 1, A is CH2 or a bond, B is CH2 or carbonyl, D is CH2 or carbonyl, E is CH2 or NR^, G is CH2 or a bond, Q is CH2 or carbonyl, T is CH2 or NR29, R19 represents hydrogen, CrC4alkyl, phenyl-d-C4alkyl, CrC4alkylcarbonyl or CrC4alkyl-S02-, R^ is hydrogen and R29 is phenyl;<br>
(d)	a radical of substructure le<br>
which is bound to the molecule via the nitrogen atom, wherein<br>
R27 is CrC4alkyl or CrC4alkylcarbonyl and R28 is hydrogen, Ci-C4alkoxy or halogen; or<br>
(e)	NR20R2i, wherein R20 and R2? are independently selected from hydrogen, CrC4alkyI,<br>
C3-C7cycloalkyl which is unsubstituted or monosubstituted by hydroxy; and phenyl which<br>
is unsubstituted or monosubstituted by 1,2,3-thiadiazol-4-yl, under the proviso that not<br>
both R20 and R21 can represent hydrogen at the same time; and<br><br>
R2 denotes Ci-C8alkyl, which is unsubstituted or substituted by C3-C7cycloalkyi which is unsubstituted or disubstituted by halogen; phenyl, which is mono- or disubstituted by halogen;  .<br>
under the proviso that R2 does not represent 1,1-dimethyIethyl, if<br>
(a)	Ri is benzo[b]imidazol-1-yl, 1-imidazolyl, 4f5-dichloro-1-imidazolyl, 2-(CrC4alkyl)-1-imidazolyl, imidazolidin-2,5-dion-1-yl, 5,5-dimethyl-oxazoIidin-2,4-dion-3-yl, 1H-1,2,3-triazol-1-yl, 2H-1,2,3-triazol-2-yl, S-nitro-IH-l^-triazoM-yl, 2H-tetrazol-2-yl or 1H-tetrazol-1-yl, or if Rt is a radical of substructure lc, R23 to R26 are hydrogen, X is NR18 and RIB is hydrogen, methyl, ethyl, acetyl, 4-pyridyi, 1-piperidinyl, phenyl, methoxyphenyl, ethoxyphenyl, fluorophenyl or chlorophenyl;<br>
(b)	R, is a radical of substructure !c, R2S to R23 aro hydrogen, X Is -(r-H2}s CRi7R*B-i * is 0, and R17 and Ri8 are selected from hydroxyl and phenyl which is monosubstituted by chloro or Ri7 and R18 are selected from hydrogen, methoxyphenyl and N-phenyl-carbarnoyl; or<br>
(c)	Ri is a radical of substructure Id, k is 1, A is a bond, E is NR^, R22 is hydrogen, G, Q and T are CH2, B and D are carbonyl and R19 is methyl, n-propyl or iso-butyl;<br>
under the proviso that R2 does not represent 2-methylpropyl, if R^ is a radical of substructure Id, k is 1, A is a bond, E is NR22, R22 is hydrogen, G, Q and T are CH2, B and D are carbonyl and R19 is methyl, or if Ri is a radical of substructure lc, R23 to R26 are hydrogen, X is "(CH2)S-CR17R18-, s is 0, and Ri7 and R18 are selected from hydrogen and phenyl which is monosubstituted by methoxy;<br>
and under the proviso that R2 does not represent 1-methyiethyl, if R1 is a radical of substructure lc, R23 to R26 are hydrogen, X is NRi8 and R18 is methoxyphenyl or ethoxyphenyl, or X is CRi7R18 and R17 and R?8 are selected from hydrogen and methoxyphenyl;<br>
or a tautomer thereof,<br>
or a salt of such pyrrolo pyrimidine or its tautomer.<br>
♦3. A pyrrolo pyrimidine of formula I according to claim 1 or 2, or an N-oxide or a tautomer thereof, or a pharmaceutical^ acceptable salt of such a compound, for use in a method for the treatment of the human or animal body.<br><br>
4.	Use of a pyrrolo pyrimidine of formula I according to claim 1 or 2, or an N-oxide or a tautomer thereof, or a pharmaceutically acceptable salt of such a compound, for the preparation of a pharmaceutical product for the treatment of neuropathic pain.<br>
5.	A method for the treatment of neuropathic pain, which comprises administering a pyrrolo pyrimidine of formula I according to claim 1 or 2, or a N-oxide or a tautomer thereof, or a pharmaceutically acceptable salt thereof, its N-oxide or its tautomer, in a quantity effective against said disease, to a warm-blooded animal requiring such treatment.<br>
6.	A pharmaceutical preparation, comprising a pyrrolo pyrimidine of formula I according to claim t or 2, or an N-oxide or a tautomer thereof, or a pharmaceutically acceptable salt of such a compound, or a hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier.<br>
7.	A process for the preparation of a pyrrolo pyrimidine of formula I<br><br>
wherein Y represents -(CH2)rO- or (CH2)r-S-<br>
p is 1 or 2,<br>
ris 1,2 or 3,<br>
tis1,2or3,<br>
fy represents<br>
(v) phenyl which is unsubstituted or mono-, di- or trisubstituted by<br>
(a) halogen, carboxy, alkoxy, nitro, alkyl-C(0)-NH-, cycIoaIkyl-G(0)-NH-, alkyl-C(O)-N(alkyl)-( formyl, alkyl-C(O)-, alkyl-S(0)2-NH-t CF3-alkyl-S(0)2-NH-f pyrrolidinyl carbonyl, piperidinyl carbonyl, morpholinyl carbonyl, N-alkyl piperazinyl carbonyl, piperidinyl, 1-(alkyl carbonyl) piperidinyl, 1,2,3,6-tetrahydropyridyl, alkyl carbonyl 1,2,3,6-tetrahydropyridyl, piperazinyl, alkyl piperazinyl, alkyl carbonyl piperazinyl, cycloalkyl carbonyl piperazinyl, alkoxy carbonyl piperazinyl, alkyl-S02-plperazinyl, diazacycloheptyl, alkyl carbonyl diazacycloheptyl, 2-oxo-1 -pyrrolidinyl, 3,3-di-alkyl-2-<br><br>
oxo-1-pyrrolidinyl;<br>
(P) fValkyl, wherein R3 represents hydrogen, hydroxy, carboxy, alkyl-N(alkyl)-, alkyl-<br>
NH-, 1-pynrolidinyl, 1-piperidyl, 4-aikyl-1-piperazinyl carbonyl, 2,4-dioxa-5,5-(di-alkyl)-<br>
oxazolidin-3-yl, R4R5N-C(0)-, wherein R4 and R5 independently of each other<br>
represent hydrogen or alkyl; or<br>
(y) ReR7N-C(0)-( wherein R6 and R7 independently of each other represent hydrogen,<br>
alkyl, cycloalkyl alkyl, CF3-alkyl or pyridyl alkyl; (w) pyridyl, which Is unsubstituted or mono-, di- or trisubstituted by halogen or alkyl which<br>
is mono-, di- or trisubstituted by halogen; (x) pyrimidyl;<br>
(y) »ndolyl, which is mono- or disubstituted by aIkyl-C(0)-NH-a!kyl;. (z) 2-(alkyl)-benzothiazolyl; (aa)     a radical of subformula la<br><br>
wherein R8 is hydrogen, halogen or alkyl, R9 is hydrogen or alkyl, and m is 1, 2, 3 or 4; or (bb)     a radical of subformula lb<br><br>
wherein Rio is hydrogen, halogen or alkyl, Rn is hydrogen or alkyl, and n is 1,2, 3 01<br>
4; R2 represents alkyl, which is unsubstituted or substituted by cycloalkyl, which is unsubstituted or mono- or disubstituted by halogen, or phenyl, which is mono- or disubstituted by halogen;<br><br>
under the proviso that R2 does not represent 1,1-dimethylethyl if Y is O and fy is selected from 3-pyridyl, 4-pyridyl, 5-chloro-3-pyridyl, 6-chloro-3-pyridyl, 2-chloro-4-pyridyl, 2-trifIuoromethyl-4-pyridyI, 2-difluoromethyl-4-pyridyl, 4-acetyM-piperazinyl-phenyl, 4-methyl-1 -piperazinyl-methyl-phenyl, and<br>
under the proviso that R2 does not represent 1,1-dimethylethyl, if Y is S and Ri is 4-pyridyl;<br>
wherein an alcohol or a thiol of formula llv<br>
Rr(Y)p-H	(II)<br>
wherein Y represents -(CH2)rO- or (CH2)rS- and t, r and R^ have the meanings as provided above for a compound of formula I, is alkylated with a pyrrolp pyrimidine of formula Si I<br><br>
wherein R2 has the meaning as provided above for a compound of formula I and Hal denotes halo, preferably bromo,<br>
wherein the starting compounds of formula II and III may also be present with functional groups in protected form, if necessary, and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible;<br>
wherein any protecting groups in a protected derivative of a compound of the formula I are removed;<br>
and, if so desired, an obtainable compound of formula I is converted into another compound of formula I or a N-oxide thereof, a free compound of formula I is converted into a salt, an obtainable salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.<br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwMC1jaGVucC0yMDA1LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">1800-chenp-2005-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwMC1jaGVucC0yMDA1LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">1800-chenp-2005-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwMC1jaGVucC0yMDA1LWNvcnJlc3BvbmRuZWNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">1800-chenp-2005-correspondnece-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwMC1jaGVucC0yMDA1LWNvcnJlc3BvbmRuZWNlLXBvLnBkZg==" target="_blank" style="word-wrap:break-word;">1800-chenp-2005-correspondnece-po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwMC1jaGVucC0yMDA1LWRlc2NyaXB0aW9uKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">1800-chenp-2005-description(complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwMC1jaGVucC0yMDA1LWZvcm0gMS5wZGY=" target="_blank" style="word-wrap:break-word;">1800-chenp-2005-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwMC1jaGVucC0yMDA1LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">1800-chenp-2005-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwMC1jaGVucC0yMDA1LWZvcm0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">1800-chenp-2005-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwMC1jaGVucC0yMDA1LWZvcm0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">1800-chenp-2005-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwMC1jaGVucC0yMDA1LXBjdC5wZGY=" target="_blank" style="word-wrap:break-word;">1800-chenp-2005-pct.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="229389-dental-face-bow.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="229392-a-composition-comprising-nsidi-and-nsidie-for-decreasing-proinflammatory-cytokine-secretion.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>229390</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1800/CHENP/2005</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>12/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>20-Mar-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>17-Feb-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>03-Aug-2005</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>NOVARTIS AG</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>Lichtstrasse 35, CH-4056 Basel,</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>IWASAKI, Atsuko</td>
											<td>2-4-1 Amakubo, Tsukuba-shi, Ibaraki Pref. 305-0005,</td>
										</tr>
										<tr>
											<td>2</td>
											<td>KANAZAWA, Takanori</td>
											<td>27-8-203, Higashi-arai, Tsukuba-shi, Ibaraki Pref. 305-0033,</td>
										</tr>
										<tr>
											<td>3</td>
											<td>MASUYA, Keiichi</td>
											<td>1-2-1 Tsukuho, Tsukuba-shi, Ibaraki Pref. 300-3257,</td>
										</tr>
										<tr>
											<td>4</td>
											<td>NONOMURA, Kazuhiko</td>
											<td>66-1 D Nishi-ohashi, Tsukuba-shi, Ibaraki-Pref. 305-0831,</td>
										</tr>
										<tr>
											<td>5</td>
											<td>SNELL, Christopher, Robert</td>
											<td>The Cottage, Thorpeland Lane, Runcton Holme, Norfolk, PE33 0AF,</td>
										</tr>
										<tr>
											<td>6</td>
											<td>SONG, Chuanheng</td>
											<td>11 Fiddleneck Lane, Southborough, MA 01772,</td>
										</tr>
										<tr>
											<td>7</td>
											<td>TANABE, Keiko</td>
											<td>13-2-107 Kitakashiwadai, Kashiwa-shi, Chiba Pref. 277-08356,</td>
										</tr>
										<tr>
											<td>8</td>
											<td>BUXTON, Francis, Paul</td>
											<td>376 Highland Avenue, Winchester, MA 01890,</td>
										</tr>
										<tr>
											<td>9</td>
											<td>EHARA, Takeru</td>
											<td>2-17-3-401 Ninomiya, Tsukuba-shi, Ibaraki Pref. 305-0051,</td>
										</tr>
										<tr>
											<td>10</td>
											<td>GANJU, Pamposh</td>
											<td>Novartis Institute for Medical Sciences, 5 Gower Place, London WC1E 6BS,</td>
										</tr>
										<tr>
											<td>11</td>
											<td>HALLETT, Allan</td>
											<td>Novartis Institute for Medical Sciences, 5 Gower Place, London WC1E 6BS,</td>
										</tr>
										<tr>
											<td>12</td>
											<td>IRIE, Ozamu</td>
											<td>4072-3-102 Ohzone, Tsukuba-shi, Ibaraki Pref. 300-3253,</td>
										</tr>
										<tr>
											<td>13</td>
											<td>SAKAKI, Junichi</td>
											<td>4-5-9, Ninomiya, Tsukuba-shi, Ibaraki Pref. 305-0051,</td>
										</tr>
										<tr>
											<td>14</td>
											<td>YOKOKAWA, Fumiaki</td>
											<td>2-4-6-13, Sengen Tsu,uba-shi, Ibaraki Pref. 305-0047,</td>
										</tr>
										<tr>
											<td>15</td>
											<td>TENO, Naoki</td>
											<td>1-25-12, Kamikashiwada, Ushiku-shi, Ibaraki Pref. 300-1232,</td>
										</tr>
										<tr>
											<td>16</td>
											<td>UMEMURA, Ichiro</td>
											<td>2-3-7-406, Ninomiya, Tsukuba-shi, Ibaraki Pref. 305-0051,</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K31/519</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2004/001081</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2004-02-05</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>0302748.9</td>
									<td>2003-02-06</td>
								    <td>U.K.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>0304641.4</td>
									<td>2003-02-28</td>
								    <td>U.K.</td>
								</tr>
								<tr>
									<td>3</td>
									<td>0304642.2</td>
									<td>2003-02-28</td>
								    <td>U.K.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/229390-2-cyanopyrrolopyrimidines-and-process-for-preparing-the-same by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 10:04:47 GMT -->
</html>
